These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 25630291)

  • 41. Oral anticoagulant monitoring: Are we on the right track?
    Onundarson PT; Flygenring B
    Int J Lab Hematol; 2019 May; 41 Suppl 1():40-48. PubMed ID: 31069986
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
    Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
    Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Biological monitoring and prevention of complications from antithrombotic agents].
    Samama MM; Kher A
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1569-77. PubMed ID: 9092420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interest of pharmacoepidemiology for the study of anticoagulants.
    Bagheri H
    Therapie; 2019 Apr; 74(2):245-248. PubMed ID: 30683443
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis.
    Maura G; Billionnet C; Coste J; Weill A; Neumann A; Pariente A
    Drug Saf; 2018 Sep; 41(9):881-897. PubMed ID: 29714004
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of oral anticoagulant treatment in patients with venous thromboembolism.
    Pengo V
    Semin Thromb Hemost; 2006 Nov; 32(8):781-6. PubMed ID: 17171590
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel anticoagulants and the future of anticoagulation.
    Garcia D
    Thromb Res; 2009; 123 Suppl 4():S50-5. PubMed ID: 19303505
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients.
    Kooistra HA; Veeger NJ; Khorsand N; Kluin-Nelemans HC; Meijer K; Piersma-Wichers M
    Thromb Haemost; 2015 Apr; 113(4):881-90. PubMed ID: 25518854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Should we fear direct oral anticoagulants more than vitamin K antagonists in simple single tooth extraction? A prospective comparative study.
    Berton F; Costantinides F; Rizzo R; Franco A; Contarin J; Stacchi C; Maglione M; Visintini E; Di Lenarda A; Di Lenarda R
    Clin Oral Investig; 2019 Aug; 23(8):3183-3192. PubMed ID: 30392079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency VKA anticoagulation reversal.
    Dentali F; Imberti D; Tamburini Permunian E; Croci E; Ageno W
    Thromb Haemost; 2014 Sep; 112(3):621-3. PubMed ID: 24965568
    [No Abstract]   [Full Text] [Related]  

  • 52. [Treatment of bleeding complications due to oral anticoagulant drugs].
    Riess H
    Laryngorhinootologie; 2015 Oct; 94(10):697-709. PubMed ID: 26468622
    [No Abstract]   [Full Text] [Related]  

  • 53. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
    Leung TS; Law EH
    Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Testing and monitoring direct oral anticoagulants.
    Connors JM
    Blood; 2018 Nov; 132(19):2009-2015. PubMed ID: 30201757
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment.
    Tran E; Duckett A; Fisher S; Bohm N
    J Thromb Thrombolysis; 2017 May; 43(4):505-513. PubMed ID: 28271315
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Four-factor prothrombin complex concentrate versus plasma for urgent vitamin K antagonist reversal: new evidence.
    Sarode R
    Clin Lab Med; 2014 Sep; 34(3):613-21. PubMed ID: 25168946
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
    Darius H
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of New Oral Anticoagulants for Patients with Chronic Kidney Disease.
    Zbigniew K; Hubert S; Andrzej J; Michal S
    Curr Pharm Des; 2018; 24(38):4505-4510. PubMed ID: 30706805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Levine MN; Raskob G; Beyth RJ; Kearon C; Schulman S
    Chest; 2004 Sep; 126(3 Suppl):287S-310S. PubMed ID: 15383476
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.